Perspective Therapeutics CATX Income Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $91.26M+8.4% | $84.22M+31.2% | $64.17M+14.9% | $55.86M+15.1% | $48.52M+16.5% | ||
| $29.38M-2.8% | $30.23M-4.1% | $31.53M+2.5% | $30.77M+7.7% | $28.58M+7.4% | ||
| $120.63M+5.4% | $114.45M-4.5% | $119.79M+8.2% | $110.72M+9.4% | $101.18M+9.6% | ||
| -$120.01M-5.7% | -$113.56M+4.3% | -$118.72M-8.4% | -$109.49M-9.8% | -$99.71M-9.7% | ||
| $7.57M-17.1% | $9.14M-11.3% | $10.31M-13.6% | $11.93M-7.8% | $12.93M+23.7% | ||
| —— | -$104.43M+3.7% | -$108.41M-11.1% | -$97.56M-12.4% | -$86.78M-7.9% | ||
| -$111.13M-7.8% | -$103.12M+2.5% | -$105.8M-11.4% | -$94.95M-11.5% | -$85.17M-7.4% | ||
| -$1.400.0% | -$1.40+6.7% | -$1.50-10.3% | -$1.36-8.8% | -$1.250.0% | ||
| -$116.37M-5.5% | -$110.31M+4.7% | -$115.77M-8.6% | -$106.65M-9.9% | -$97.03M-9.5% | ||
| -$120.01M-5.7% | -$113.56M+4.3% | -$118.72M-8.4% | -$109.49M-9.8% | -$99.71M-9.7% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Perspective Therapeutics's revenue?
- Perspective Therapeutics (CATX) generated $10.0M in revenue over the trailing twelve months, up 0.5% year over year.
- Is Perspective Therapeutics profitable?
- Perspective Therapeutics is not currently profitable: it reported a net loss of $111.1M over the trailing twelve months, a -218.4% net margin.
- What are Perspective Therapeutics's profit margins?
- Gross margin is 33.1% and operating margin is -292.7%, with a -218.4% net margin.
- What is Perspective Therapeutics's earnings per share?
- Perspective Therapeutics's diluted EPS over the trailing twelve months is $-1.40.
- Where does Perspective Therapeutics's income statement data come from?
- Every line is extracted from Perspective Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
